At a glance
| Peptide length | 6 amino acids |
|---|---|
| Primary pathway | Ghrelin / GH-secretagogue receptor |
| Human evidence | Small physiology studies |
| FDA concern | Cortisol and insulin-sensitivity effects |
| Clinical benefit gap | No established recovery or longevity outcome |
Overview
GHRP-6 is one of the earlier synthetic GH-releasing peptides and helped researchers investigate regulation of pituitary secretion. Its clinical literature is largely focused on short-term hormonal responses rather than patient-centered outcomes. A prolonged-infusion experiment in healthy men showed changes in GH pulses and IGF-1, but it was not a trial of athletic rehabilitation or treatment of age-related disability. It is distinct from GHRP-2, hexarelin, and ipamorelin, despite overlapping receptor biology. Findings from one member of this family should not be attributed automatically to every other member, particularly claims based on animal cardiac experiments.
How it works
GHRP-6 activates growth hormone secretagogue receptors, now understood as part of the ghrelin signaling system, and acts with hypothalamic–pituitary regulation to increase GH secretion. Its effects can interact with GHRH and somatostatin. GH signaling may increase IGF-1, while other endocrine effects and reduced insulin sensitivity complicate interpretation. A response depends on the administration pattern and baseline physiology, rather than being a fixed measure of clinical benefit.
A physiology study, not a performance trial
A study in nine healthy young men compared a prolonged GHRP-6 infusion with saline. GH pulse amplitude and overall GH exposure increased, with an IGF-1 rise. Other pituitary responses also changed. The study demonstrates endocrine activity and adaptation, but its size and duration cannot establish long-term efficacy or safety.
Supporting sources [1]
Metabolic and product-related uncertainty
FDA identifies limited safety data and concerns about cortisol effects and increased blood glucose from reduced insulin sensitivity. It also describes immune-reaction risks related to aggregation and peptide impurities. A seller’s claim that the molecule is naturally inspired does not answer those preparation or endocrine questions.
Supporting sources [2]
No established US therapeutic indication
GHRP-6 is not an FDA-approved treatment for sarcopenia, injuries, obesity, or healthy aging. Its status in compounding policy is a separate regulatory issue from evidence of therapeutic benefit. The available human research should be reported as experimental physiology unless a specific clinical outcome has actually been demonstrated.
Can hexarelin cardiac results be cited for GHRP-6?
They should not be treated as direct evidence. A frequently cited CD36 experiment specifically used hexarelin in animal cardiac systems and included increased coronary perfusion pressure. Related molecules may share some biology, but that study does not demonstrate that GHRP-6 protects human hearts or improves exercise recovery.
Supporting sources [3]
Reading this profile
Jurisdiction: United States: no FDA-approved GHRP-6 medicine.. Molecular class: Synthetic hexapeptide growth hormone secretagogue.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. ↗Original research · Checked 2026-10-27
- FDA — bulk substances with potential significant safety risks ↗Regulatory source · Checked 2026-10-27
- CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. ↗Original research · Checked 2026-10-27